Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study
Nachuan Zou, Yiqiao Li, Zhe Huang, Tian Xu, Fang Tian, Huan Yan et al. Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study. // BMC Cancer. – 2026. – DOI: 10.1186/s12885-026-17206-5. – URL: https://doi.org/10.1186/s12885-026-17206-5
Nachuan Zou, Yiqiao Li, Zhe Huang, Tian Xu, Fang Tian, Huan Yan, Jiacheng Dai, Xianling Liu, Liang Zeng, & Yongchang Zhang (2026). Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17206-5
Nachuan Zou, et al. “Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study.” BMC Cancer, 2026. doi:10.1186/s12885-026-17206-5.
@article{Zou2026,
title = {Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study},
author = {Zou, Nachuan and Li, Yiqiao and Huang, Zhe and Xu, Tian and Tian, Fang and Yan, Huan and Dai, Jiacheng and Liu, Xianling and Zeng, Liang and Zhang, Yongchang},
journal = {BMC Cancer},
year = {2026},
doi = {10.1186/s12885-026-17206-5},
url = {https://doi.org/10.1186/s12885-026-17206-5}
}